Nothing said here yet.
to join the conversation.
| Scholl Hendrik PeterChief Medical Officer | Sell | 200 | $32.7K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 120 | $19.9K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 78 | $13.1K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 50 | $8.3K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 24 | $4.0K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 14 | $2.4K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 12 | $2.0K | Thu, Oct 1 |
| Scholl Hendrik PeterChief Medical Officer | Sell | 2 | $340 | Thu, Oct 1 |
| Lin Yu-HsinChief Executive Officer | Sell | 8,752 | $1.7M | Tue, Sep 8 |
| Lin Yu-HsinChief Executive Officer | Sell | 6,090 | $1.2M | Tue, Sep 8 |
| Lin Yu-HsinChief Executive Officer | Sell | 6,058 | $1.2M | Tue, Sep 8 |
| Chuang Hao-YuanChief Financial Officer | Sell | 4,605 | $908.2K | Tue, Sep 8 |
Belite Bio submitted Marketing Authorization Applications for tinlarebant to regulators in Singapore, the United Kingdom, and Switzerland under the Access Consortium framework for treating Stargardt disease type 1, which currently has no approved therapies in…
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date.
SAN DIEGO, Sept.
Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that accompanies the company’s latest quarterly earnings report. See our latest analysis for Belite Bio.
Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to a less straightforward picture of how much is already priced in.